CliffBio
biologic

Aimovig

erenumab-aooe

Loss of exclusivityMarch 2031projected — 12-year biologic exclusivity estimate
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameAimovig
Active ingredienterenumab-aooe
Strength140MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMarch 2019
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.